Tandem mass spectrometry study of p38a kinase inhibitors and related substances

D. Falck, J. Kool, M. Honing, W.M.A. Niessen

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

The p38 mitogen-activated protein kinase α (p38α) is an important drug target widely investigated for therapy of chronic inflammatory diseases. Its inhibitors are rather lipophilic and as such not very favourable lead compounds in drug discovery. Therefore, we explored various approaches to access new chemical space, create diversity, and generate lead libraries with improved solubility and reduced lipophilicity, based on known p38α inhibitors, e.g., BIRB796 and TAK-715. Compound modification strategies include incubation with human liver microsomes and bacterial cytochrome P450 mutants from Bacillus megaterium and treatment by electrochemical oxidation, H
Original languageEnglish
Pages (from-to)718-731
JournalJournal of Mass Spectrometry
Volume48
DOIs
Publication statusPublished - 2013

    Fingerprint

Cite this